Youngman Oh, M.S., Ph.D.
Research program member: Developmental Therapeutics
1101 E. Marshall St.
Richmond, VA 23298
Professor, Pathology, School of Medicine
PhD, Stanford University (1993)
MS, Eastern Michigan University (1987)
My laboratory has discovered an entirely distinct anti-tumor and anti-metastatic signaling pathway through a new class of cell death receptor, known as TMEM219. We have further obtained two monoclonal antibodies (mAbs) that activate the TMEM219 receptor, so-called "agonistic antibodies." Currently, my laboratory focuses on therapeutic potential of those TMEM219 mAbs as a monotherapy or a combinational therapy with chemodrugs and immune checkpoint inhibitors in breast, lung, colon, and pancreatic cancer and AML.
Angiogenesis,Animal models,Apoptosis,Biomarkers,Cancer cell biology,Cancer therapy resistance,Cell signaling,Drug discovery,Immunotherapy,Inflammation,Obesity,Signal transduction,Targeted therapies,Translational science